EMPA-REG OUTCOME: The Cardiologist's Point of View
- PMID: 28606345
- DOI: 10.1016/j.amjcard.2017.05.011
EMPA-REG OUTCOME: The Cardiologist's Point of View
Abstract
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
Similar articles
-
EMPA-REG OUTCOME: The Cardiologist's Point of View.Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006. Am J Med. 2017. PMID: 28526181
-
EMPA-REG OUTCOME: The Endocrinologist's Point of View.Am J Med. 2017 Jun;130(6S):S51-S56. doi: 10.1016/j.amjmed.2017.04.005. Am J Med. 2017. PMID: 28526185
-
EMPA-REG OUTCOME: The Endocrinologist's Point of View.Am J Cardiol. 2017 Jul 1;120(1S):S48-S52. doi: 10.1016/j.amjcard.2017.05.010. Epub 2017 May 17. Am J Cardiol. 2017. PMID: 28606344 Review.
-
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.Am J Med. 2017 Jun;130(6S):S30-S39. doi: 10.1016/j.amjmed.2017.04.009. Am J Med. 2017. PMID: 28526184 Review.
-
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.Am J Cardiol. 2017 Jul 1;120(1S):S28-S36. doi: 10.1016/j.amjcard.2017.05.013. Epub 2017 May 30. Am J Cardiol. 2017. PMID: 28606341 Review.
Cited by
-
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.Endocrinol Metab (Seoul). 2019 Jun;34(2):106-116. doi: 10.3803/EnM.2019.34.2.106. Epub 2019 May 9. Endocrinol Metab (Seoul). 2019. PMID: 31099200 Free PMC article. Review.
-
Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.J Diabetes Investig. 2018 Jul;9(4):882-892. doi: 10.1111/jdi.12787. Epub 2018 Jan 8. J Diabetes Investig. 2018. PMID: 29215196 Free PMC article.
-
Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors.Diabetes Metab Syndr Obes. 2019 Dec 5;12:2559-2566. doi: 10.2147/DMSO.S223629. eCollection 2019. Diabetes Metab Syndr Obes. 2019. PMID: 31824184 Free PMC article.
-
Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes.J Clin Med. 2020 Nov 23;9(11):3779. doi: 10.3390/jcm9113779. J Clin Med. 2020. PMID: 33238573 Free PMC article.
-
Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.Transpl Int. 2021 Jan;34(1):27-48. doi: 10.1111/tri.13783. Epub 2020 Nov 28. Transpl Int. 2021. PMID: 33135259 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
